CPT® Code 81282

Official Description

Long QT syndrome gene analyses (eg, KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP, SNTA1, and ANK2); duplication/deletion variants

Common Language Description

Molecular genetic testing is a critical process used to identify specific gene mutations that are responsible for long QT syndrome (LQTS). Long QT syndrome is a rare, inherited cardiac condition characterized by delayed repolarization of the heart, which can lead to serious complications. This condition is particularly sensitive to adrenergic stimulation, which can occur during activities such as exercise or excitement. The mutations associated with LQTS prolong the duration of the ventricular action potential, resulting in an extended QT interval on an electrocardiogram (ECG). Individuals diagnosed with LQTS face an increased risk of developing irregular heart rhythms, experiencing cardiac palpitations, suffering syncopal episodes (fainting), and even facing sudden death due to ventricular fibrillation. The genetic mutations linked to LQTS can be inherited in an autosomal recessive or dominant manner. More severe recessive phenotypes may also present with additional physical anomalies, such as syndactyly (fused fingers or toes) and/or congenital neural deafness. The testing process includes a full sequence analysis, which compares segments of genes to identify similarities or differences and to establish relationships among them. This analysis examines intrinsic features to locate active sites for post-translational modifications, as well as the structures of genes, including the distribution of introns, exons, and regulatory elements. Genetic markers are identified through the detection of point mutations or single nucleotide polymorphisms (SNPs). The most prevalent mutation associated with LQTS, known as LQT1, is located on the KCNQ1 gene found on chromosome 11 and is present in approximately 30-35% of individuals diagnosed with this syndrome. In cases where a familial variant has been identified, it is recommended that all first-degree relatives undergo molecular genetic testing to assess their risk factors. This genetic mapping can reveal common or familial variants among blood relatives. Specifically, CPT® Code 81282 pertains to the analysis of deletion and duplication variants in the genes associated with LQTS. A normal gene typically has two copies per cell, with exceptions for sex chromosomes; thus, the presence of zero or one copy indicates a deletion variant, while three or more copies suggest a duplication variant. Notably, the genes KCNH2 and SCN5A have been recognized as associated with these types of variants, which can also involve substitutions or changes in the amino acid sequencing of the gene.

1. Indications

The molecular genetic testing for long QT syndrome gene analyses is indicated for the following conditions:

Long QT Syndrome (LQTS) - A condition characterized by delayed repolarization of the heart, leading to an increased risk of irregular heart rhythms and other cardiac complications.
Familial Variants - Testing is recommended for first-degree relatives of individuals diagnosed with LQTS to identify potential genetic risks.
Associated Physical Anomalies - Individuals presenting with syndactyly or congenital neural deafness may also be evaluated for LQTS-related genetic mutations.

2. Procedure

The procedure for long QT syndrome gene analyses involves several key steps to ensure accurate identification of genetic mutations:

Sample Collection A biological sample, typically blood or saliva, is collected from the patient to obtain DNA for analysis. This sample serves as the basis for the genetic testing process.
DNA Extraction The DNA is extracted from the collected sample using standardized laboratory techniques. This step is crucial for isolating the genetic material needed for further analysis.
Gene Analysis The extracted DNA undergoes a detailed analysis focusing on specific genes associated with long QT syndrome, including KCNQ1, KCNH2, SCN5A, and others. This analysis aims to identify any deletion or duplication variants present in the genes.
Variant Interpretation The results of the gene analysis are interpreted to determine the presence of any genetic mutations. This includes assessing the number of gene copies to identify deletion (zero or one copy) or duplication (three or more copies) variants.
Reporting Results A comprehensive report is generated, detailing the findings of the genetic analysis. This report includes information on any identified mutations, their potential implications for the patient and their family, and recommendations for further testing if necessary.

3. Post-Procedure

After the completion of the long QT syndrome gene analyses, patients may receive counseling regarding the results and their implications. If a genetic mutation is identified, it is recommended that first-degree relatives undergo testing to assess their risk. Additionally, healthcare providers may discuss potential management strategies for individuals diagnosed with LQTS, including lifestyle modifications and monitoring for cardiac symptoms. Follow-up appointments may be scheduled to review the results and any necessary interventions based on the findings of the genetic testing.

Short Descr	LONG QT SYN GENE DUP/DLT VAR
Medium Descr	LONG QT SYNDROME GENE ANAL DUP/DEL VARIANTS
Long Descr	Long QT syndrome gene analyses (eg, KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP, SNTA1, and ANK2); duplication/deletion variants
Status Code	Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	9 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
APC Status Indicator	Service Paid under Fee Schedule or Payment System other than OPPS
Type of Service (TOS)	5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS)	T1H - Lab tests - other (non-Medicare fee schedule)
MUE	Not applicable/unspecified.
CCS Clinical Classification	234 - Pathology